Artesunate + Sulfadoxine-Pyrimethamine (AS-SP) Regimen for Uncomplicated P. falciparum Malaria
AS-SP is NOT recommended as first-line treatment for uncomplicated P. falciparum malaria based on current 2024 guidelines; artemether-lumefantrine or dihydroartemisinin-piperaquine are the preferred first-line artemisinin-based combination therapies (ACTs). 1
Current Treatment Recommendations
The 2024 Clinical Microbiology and Infection guidelines explicitly recommend artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DHA-PPQ) as first-line treatment for uncomplicated P. falciparum malaria in non-endemic settings 1. AS-SP is notably absent from the recommended treatment algorithms in these most recent guidelines.
First-Line ACT Regimens (2024 Guidelines):
Artemether-Lumefantrine:
- Dosing: For patients >35 kg: 4 tablets at hours 0 and 8 on day 1, then 4 tablets at hours 36,48,60, and 72 (total 24 tablets over 3 days)
- Must be taken with fatty meal or drink
- Avoid in patients with QTc prolongation risk 1
Dihydroartemisinin-Piperaquine:
- Dosing: 36-75 kg: 3 tablets daily for 3 days; >75 kg: 4 tablets daily for 3 days
- Must be taken fasting
- Avoid in patients with QTc prolongation risk 1
Historical AS-SP Regimen (When Used)
When AS-SP was used in research settings and endemic countries, the standard regimen was:
Artesunate: 4 mg/kg/day for 3 days (days 0,1,2)
Sulfadoxine-Pyrimethamine: Single dose on day 0 (25 mg/kg sulfadoxine, 1.25 mg/kg pyrimethamine) 2, 3, 4, 5
Critical Evidence on AS-SP Duration:
Three days of artesunate is essential - not one day. Studies consistently showed:
- 3-day AS-SP: Day 28 cure rate 74.4% 2, significantly better efficacy
- 1-day AS-SP: Day 28 cure rate only 45.2% 2, inadequate protection
- The 3-day regimen achieved RR 1.8 (95% CI 1.5-2.3) for cure versus SP alone 2
Why AS-SP Is No Longer Recommended
Declining Efficacy Due to Resistance:
High failure rates in areas with SP resistance: Studies from Kenya showed 46% treatment failure at day 28 with SP alone, and even with 3-day artesunate addition, failure remained at 26% 3
Molecular resistance markers: Quintuple dhfr/dhps mutations are now widespread, increasing treatment failure risk 3.2-fold 6. Somalia data showed 89% prevalence of quintuple mutations with 12.3% PCR-corrected failure rate 7
Superior alternatives available: Meta-analysis showed AL achieved 98.9% treatment success versus 97.1% for AS-SP 8
Geographic Variation in Efficacy:
- Sudan (2005): AS-SP showed 99.3% adequate response 4
- Afghanistan (2016): Maintained >95% efficacy after 10 years 9
- Somalia (2017): Failed with 12.3% failure rate, leading to policy change to AL 7
- Mozambique (2009): AS-SP achieved 98% cure rate but SP alone only 90.4% 6
Pediatric Considerations
The evidence base for AS-SP in children under 5 years is limited, representing a significant gap 10. The 2024 guidelines do not provide separate pediatric dosing for AS-SP, further supporting its non-recommended status.
Safety Profile
AS-SP was generally well-tolerated in historical studies with mild adverse effects (headache, dizziness, gastrointestinal symptoms) 2, 3, 4, 5. However, this does not overcome the efficacy concerns.
Clinical Algorithm
For uncomplicated P. falciparum malaria:
- First-line: Artemether-lumefantrine OR dihydroartemisinin-piperaquine 1
- Second-line: Atovaquone-proguanil 1
- Third-line: Mefloquine or quinine plus doxycycline/clindamycin 1
AS-SP should only be considered in resource-limited endemic settings where:
- First-line ACTs are unavailable
- Local resistance patterns demonstrate maintained efficacy (>95% cure rate)
- Molecular surveillance shows low prevalence of quintuple mutations
- Always use 3-day artesunate regimen, never 1-day 2, 3
Critical Pitfall
Never use 1-day artesunate with SP - this provides inadequate partner drug protection and leads to high failure rates (45-55% at day 28) 2. The 3-day artesunate regimen is mandatory if AS-SP must be used.